CONRAY 325
LOE Approachingiothalamate sodium
NDAINJECTIONINJECTABLE
Approved
Sep 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CONRAY 325 (iothalamate sodium) is clinical pharmacology the renal clearance of sodium iothalamate in man closely approximates that of inulin. First approved in 1976.
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CONRAY 325 is a sodium iothalamate injection approved in 1976 for diagnostic imaging, specifically measuring glomerular filtration rate (GFR) and renal function. The drug is cleared by glomerular filtration without tubular secretion or reabsorption, closely mimicking inulin clearance. It is administered intravenously as a radiopharmaceutical agent for nephrological assessment.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching, indicating a contracting team focused on transition planning and generic mitigation strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY The renal clearance of sodium iothalamate in man closely approximates that of inulin. The compound is cleared by glomerular filtration without tubular secretion or reabsorption. Following infusion administration of I-125 iothalamate, the effective half-life is about 0.07 days.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CONRAY 325 offers limited career growth opportunities given the product's LOE-approaching status and minimal linked job postings (0). Roles are primarily defensive, focused on protecting market position, managing generic transition, and maximizing remaining exclusivity period rather than driving expansion or innovation.
Product Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.